Last reviewed · How we verify
Conditioning treatment prior to allogeneic haematopoietic stem cell transplant — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Campath | ALEMTUZUMAB | Sanofi | CD52-directed Cytolytic Antibody [EPC] | CAMPATH-1 antigen | 2001-01-01 | |
| Campath | Campath | National Heart, Lung, and Blood Institute (NHLBI) | CAMPATH-1 antigen |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in Conditioning treatment prior to allogeneic haematopoietic stem cell transplant
- Sanofi · 1 drug in Conditioning treatment prior to allogeneic haematopoietic stem cell transplant
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Conditioning treatment prior to allogeneic haematopoietic stem cell transplant:
- Conditioning treatment prior to allogeneic haematopoietic stem cell transplant treatment updates — RSS
- Conditioning treatment prior to allogeneic haematopoietic stem cell transplant treatment updates — Atom
- Conditioning treatment prior to allogeneic haematopoietic stem cell transplant treatment updates — JSON
Cite this brief
Drug Landscape (2026). Conditioning treatment prior to allogeneic haematopoietic stem cell transplant — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/conditioning-treatment-prior-to-allogeneic-haematopoietic-stem-cell-transplant. Accessed 2026-06-10.
Related
- Conditioning treatment prior to allogeneic haematopoietic stem cell transplant full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing